New drug combo battles tough liver cancer after other treatments fail
NCT ID NCT07392866
Summary
This study compares a new combination treatment (SH006 injection plus other cancer drugs) against an existing medication (regorafenib) for advanced liver cancer. It's for patients whose cancer continued to grow despite previous immunotherapy treatment. Researchers want to see if the new combination helps people live longer without their cancer getting worse and is safe to use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, 211199, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.